Pierre Massion to direct Vanderbilt-Ingram’s early detection initiative

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

PIERRE MASSION will direct the Vanderbilt-Ingram Cancer Center’s Cancer Early Detection and Prevention Initiative. Massion is the Cornelius Vanderbilt Professor of Medicine, an Ingram Professor of Cancer Research and co-leader of the VICC Cancer Health Outcomes and Control Research Program.

“The prevention of cancer and the development of more effective strategies to detect cancer precursors and early-stage cancers, when treatment may be most effective, remain top goals of Vanderbilt University Medical Center and we are pleased that Pierre has agreed to lead this new initiative,” said Jennifer Pietenpol, executive vice president for research at VUMC and director of the cancer center. “As we develop a better understanding of environment and lifestyle factors, and common genetic variants that are associated with higher or lower risk of certain cancers, we may be able to use that knowledge to identify individuals who may benefit from early detection and prevention strategies.”

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login